Coiled Therapeutics plc (0AG)

Overview

Coiled Therapeutics plc is a clinical-stage biotechnology firm dedicated to the advancement of precision oncology medicines aimed at addressing challenging cancer types. The company primarily focuses on targeted therapies that can effectively treat aggressive solid tumors, with a particular interest in innovative small-molecule solutions that are suitable for oral intake and can penetrate the central nervous system. Coiled Therapeutics plc's current pipeline comprises oncology programs under early-stage clinical evaluation, wherein the key aspects of safety, tolerability, and biological activity are thoroughly assessed in patients suffering from advanced disease. Situated within the wider life sciences sector, Coiled Therapeutics plc plays an essential role in promoting precision medicine and biomarker-driven drug development in the realm of cancer treatment. With a commitment to tackling complex oncology challenges, the company is poised to develop specialized therapeutic options that meet considerable unmet medical needs. Coiled Therapeutics plc is headquartered in London and is steadfastly focused on propelling experimental cancer therapies through the necessary clinical development phases.

Products and Services

• Targeted Therapies: Coiled Therapeutics plc specializes in the creation of targeted therapies that aim to selectively attack cancer cells, while minimizing damage to healthy tissues. These therapies are designed to enhance the effectiveness of treatment regimens for patients suffering from aggressive solid tumors.
• Small-Molecule Approaches: The company emphasizes the development of novel small-molecule drugs that can be administered orally and possess the ability to penetrate the central nervous system. These innovative approaches are vital in addressing complex tumor types that are typically difficult to treat.
• Clinical Trials: Coiled Therapeutics plc is actively engaged in early-phase clinical studies to evaluate the safety, tolerability, and biological activity of its oncology programs. This data is crucial for understanding the potential effectiveness of its therapies.
• Precision Medicine: By utilizing precision medicine strategies, the company aims to identify specific biomarkers that can inform treatment plans, thereby enhancing the probability of successful outcomes for patients with hard-to-treat cancers.
• Oncology Programs: Coiled Therapeutics plc’s pipeline is specifically focused on oncology programs that are in the early stages of clinical development, highlighting the company's commitment to addressing significant unmet medical need in cancer care.